February 16, 2018 / 12:43 PM / 3 months ago

BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros

Feb 16 (Reuters) - Apricus Biosciences Inc:

* APRICUS BIOSCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR VITAROS

* APRICUS BIOSCIENCES INC - CRL INDICATES THAT FDA CANNOT APPROVE NDA FOR VITAROS IN ITS PRESENT FORM

* APRICUS BIOSCIENCES INC - CRL IDENTIFIES DEFICIENCIES RELATED TO CHEMISTRY, MANUFACTURING AND CONTROL FOR VITAROS

* APRICUS BIOSCIENCES - CRL ALSO IDENTIFIES CERTAIN SAFETY CONCERNS SPECIFIC TO 2.5% CONCENTRATION OF DDAIP.HCL IN CURRENT FORMULATION FOR VITAROS

* APRICUS BIOSCIENCES INC - GOAL OF PROVIDING MARKET AN UPDATE ON CRL ASSESSMENT IN EARLY MARCH OF THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below